Form 6-K PSYENCE BIOMEDICAL LTD. For: Oct 21

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2026

 

Commission File Number: 001-41937

 

Psyence Biomedical Ltd. 

(Translation of registrant’s name into English)

 

121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

☒ Form 20-F          ☐ Form 40-F 

 

 

 

EXPLANATORY NOTE

 

Investor Presentation

 

On October 21, 2026, the Company issued a press release titled “Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met.”

 

A copy of this press release is furnished as Exhibit 99.1 to this Form 6-K and is incorporated herein by reference.

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1*		Press Release, dated October 21, 2026, titled “Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met.”

 

*	Furnished herewith.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: October 21, 2026

 

Psyence Biomedical Ltd.
By:	/s/ Jody Aufrichtig
Name:	Jody Aufrichtig
Title:	Chief Executive Officer and Director

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED OCTOBER 21, 2026, TITLED "PSYENCE BIOMED COMPLETES PSYLABS INVESTMENT AS IBOGAINE MILESTONES ARE MET."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Psyence BioMed completes $2.6M PsyLabs investment after milestones met
• Boots Group Finco L.P. and The Boots Group Luxco S.à r.l. Announce Expiration and Results of the Consent Solicitation for their €650,000,000 5.375% Senior Secured Notes due 2032 and £375,000,000 7
• Wolters Kluwer launches agentic tax preparation in CCH Axcess, the agentic platform for tax and accounting